Types of CBD Oil Explained: Isolate, Full Spectrum and Broad Spectrum

Last updated: January 2026

This guide is for Australian patients, carers and healthcare consumers who want to understand the differences between CBD oil product types before speaking with a prescribing clinician. The short answer: CBD oil products fall into three main categories — isolate, full spectrum and broad spectrum — each defined by what plant compounds they contain alongside cannabidiol (CBD). Which type is appropriate depends on your clinical circumstances, and a registered prescriber should guide that choice.

What Is CBD Oil?

CBD (cannabidiol) oil is a product derived from the Cannabis sativa plant in which cannabidiol is the primary active compound, suspended in a carrier oil such as medium-chain triglyceride (MCT) oil, hemp seed oil or olive oil. In Australia, CBD oil is a prescription medicine regulated by the Therapeutic Goods Administration (TGA) under the Therapeutic Goods Act 1989. It is not a food supplement or an over-the-counter remedy for most concentrations.

One low-dose CBD product (up to 150 mg/day for adults) was down-scheduled to Pharmacist Only Medicine (Schedule 3) in 2021, but no such product had received full TGA registration for retail sale as of January 2026. All other CBD medicines remain Schedule 4 (Prescription Only) or Schedule 8 (Controlled Drug), depending on concentration and formulation.

Core Terminology: What Do These Terms Actually Mean?

CBD Isolate

An isolate contains cannabidiol as a single purified compound, typically extracted and then refined to remove all other cannabinoids, terpenes, flavonoids and plant material. The result is usually a white crystalline powder or a colourless oil that is 99%+ pure CBD. Isolates have no detectable THC, which makes them relevant where zero THC exposure is a clinical or legal priority. Because all other plant compounds have been removed, isolates do not produce an entourage effect (see below).

Full Spectrum CBD Oil

Full spectrum products retain the full range of naturally occurring compounds from the cannabis plant: multiple cannabinoids (including THC, CBG, CBC, CBN and others), terpenes, flavonoids and fatty acids. In Australia, full spectrum medicinal cannabis products must still comply with TGA requirements. Products prescribed under the Special Access Scheme or Authorised Prescriber pathway may contain THC at varying concentrations. The presence of THC means full spectrum products carry scheduling implications and are not zero-THC.

Broad Spectrum CBD Oil

Broad spectrum products occupy the middle ground. They are processed to remove or reduce THC below detectable limits while retaining most other cannabinoids, terpenes and plant compounds. The intent is to preserve some degree of multi-compound interaction without the legal and clinical considerations attached to THC. Broad spectrum is a commercial category, not a pharmacopoeial standard, so compound profiles vary between manufacturers.

Raw CBD Oil

Raw oil refers to minimally processed cannabis extract that retains cannabinoids in their acid forms — primarily CBDA (cannabidiolic acid) rather than the decarboxylated CBD. Heating or decarboxylation converts CBDA to CBD. Raw oils have a distinct compound profile and are less extensively studied than decarboxylated preparations.

CBD Concentrate

A concentrate is any extract with a significantly higher cannabinoid content than the starting plant material. Concentrates can be isolates, full spectrum or broad spectrum; the term describes potency and form (such as paste, wax or distillate) rather than compound profile.

CBD Oil vs CBD Tincture

These terms are often used interchangeably but describe different products. A CBD oil uses a lipid-based carrier (MCT oil, hemp seed oil). A tincture traditionally uses an alcohol solvent as the carrier. In practice, many products labelled "tincture" in the Australian market are oil-based, so checking the product ingredients list matters more than the label name.

How Is CBD Oil Extracted?

Extraction method affects the final compound profile and purity. The main methods used commercially are:

Supercritical CO₂ extraction: Uses pressurised carbon dioxide to extract cannabinoids and terpenes. Considered a clean method with no solvent residues; allows selective extraction of target compounds. Most commonly used by TGA-licensed manufacturers.
Ethanol extraction: Ethanol strips a broad range of compounds from plant material. Requires post-processing to remove solvent. Efficient at scale and capable of producing full spectrum extracts.
Hydrocarbon extraction (butane/propane): Effective for concentrates but requires rigorous purging to eliminate residual solvent. Less common in pharmaceutical-grade Australian production.
Lipid (oil) infusion: Plant material is steeped in a carrier oil to transfer compounds. Low-tech, low-yield; more common in artisan or DIY contexts than in licensed manufacturing.

What Is the Entourage Effect?

The entourage effect is a proposed pharmacological interaction in which the various compounds in cannabis — cannabinoids, terpenes and flavonoids — produce a combined effect that differs from any single compound in isolation. The concept was first described by researchers Raphael Mechoulam and Shimon Ben-Shabat in 1998 and has since been elaborated in the scientific literature.

Evidence for the entourage effect in humans remains preliminary. Some preclinical and observational data suggest multi-compound preparations may behave differently from isolates, but robust randomised controlled trial data comparing isolate to full or broad spectrum in specific conditions is limited as of 2026. Clinicians weighing product type will consider the available evidence alongside individual patient factors. This is not a claim that one product type is clinically superior to another.

Comparison Table: Isolate vs Broad Spectrum vs Full Spectrum

Feature	Isolate	Broad Spectrum	Full Spectrum
CBD present	Yes	Yes	Yes
Other cannabinoids	None	Yes (THC removed/reduced)	Yes (including THC)
Terpenes & flavonoids	None	Typically retained	Retained
THC present	No	None or trace	Yes (variable)
Entourage effect potential	Not applicable	Partial	Present
TGA scheduling relevance	S4 or S3 (low dose)	S4	S4 or S8 (higher THC)
Drug testing considerations	Lower risk	Low but not zero	Risk of THC detection

Scheduling reflects Australian TGA classifications. Individual product schedules depend on concentration and formulation. Confirm with your prescriber or pharmacist.

Legal Status of CBD Oil in Australia

Medicinal cannabis, including CBD products, is legal in Australia when prescribed by a registered medical practitioner through the TGA's access pathways. The main pathways are the Special Access Scheme Category B (SAS-B), the Authorised Prescriber scheme, and clinical trials. As of 2026, no CBD product specifically targeting medical conditions has been listed on the Pharmaceutical Benefits Scheme (PBS) for general reimbursement.

State and territory laws apply alongside federal TGA regulation. Driving while using products containing THC remains illegal across all jurisdictions regardless of whether the medicine is legally prescribed — roadside drug tests detect THC, not impairment. Patients prescribed full spectrum products should discuss driving and workplace obligations with their clinician.

Carrying medicinal cannabis internationally is subject to the laws of destination countries. TGA-approved documentation does not guarantee legality overseas.

How to Choose Between CBD Oil Types: Questions to Discuss With Your Clinician

No product type is universally superior. Practical questions to raise with a prescribing doctor include:

Is there clinical evidence for this condition favouring isolate or a multi-compound preparation?
Do I have occupational or legal reasons to avoid any detectable THC?
Will I be subject to workplace or roadside drug testing?
Are there drug interactions with other medicines I take?
What does the TGA-approved product information say about this formulation?
Is the product manufactured to Good Manufacturing Practice (GMP) standards?

Self-selecting a product type without clinical input carries risks, including inappropriate dosing and unrecognised interactions. Medicinal cannabis treatment in Australia is intended to occur within a supervised clinical framework.

Frequently Asked Questions

Is CBD oil the same as hemp oil?

No. Hemp seed oil is cold-pressed from cannabis seeds and contains negligible cannabinoids; it is sold as a food product. CBD oil is extracted from cannabis flowers, leaves and stalks and is regulated as a medicine in Australia. The two products have different compositions, uses and legal status.

Will CBD isolate show up on a drug test?

Pure CBD isolate does not contain THC and should not trigger a standard roadside or workplace drug test designed to detect THC. However, product mislabelling and cross-contamination in manufacturing do occur. If drug testing is a concern, your prescriber and the product's certificate of analysis (CoA) from a third-party laboratory are important references.

Can I buy CBD oil over the counter in Australia?

A Schedule 3 (Pharmacist Only) low-dose CBD pathway exists under TGA rules, but as of January 2026 no product had received full registration for pharmacy shelf sale. In practice, most patients access CBD through a prescription from a registered medical practitioner. Purchasing unregistered CBD products online from overseas sellers is not legal and carries quality and safety risks.

Does full spectrum CBD oil get you high?

THC is the primary intoxicating compound in cannabis. Full spectrum products contain THC, and at sufficient doses THC can produce psychoactive effects. The THC concentration in a prescribed full spectrum product varies, and effects depend on dose, individual sensitivity and administration route. This is one reason full spectrum products are Prescription Only and managed within a clinical relationship.

What does a certificate of analysis (CoA) show?

A CoA is a third-party laboratory report verifying a product's cannabinoid content, confirming the absence or presence of THC, and screening for contaminants such as pesticides, heavy metals and residual solvents. Reputable Australian medicinal cannabis manufacturers provide CoAs for each product batch. Reviewing the CoA helps confirm that a product matches its label claims.

Sources

Therapeutic Goods Administration — Medicinal Cannabis: https://www.tga.gov.au/products/medicinal-cannabis
TGA Scheduling Delegate's Final Decisions, February 2021 (CBD rescheduling): https://www.tga.gov.au/resources/publication/scheduling-delegates-final-decisions/scheduling-delegates-final-decisions-february-2021
Australian Government Department of Health — Medicinal Cannabis Access: https://www.health.gov.au/topics/medicinal-cannabis
Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology. 2011;163(7):1344–1364. https://doi.org/10.1111/j.1476-5381.2011.01238.x
Ben-Shabat S, Fride E, Sheskin T, et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. European Journal of Pharmacology. 1998;353(1):23–31. https://doi.org/10.1016/S0014-2999(98)00392-6
Lambert Initiative for Cannabinoid Therapeutics, University of Sydney: https://www.sydney.edu.au/lambert